Chemotherapy and the war on cancer

  title={Chemotherapy and the war on cancer},
  author={Bruce A. Chabner and Thomas G. Roberts},
  journal={Nature Reviews Cancer},
The era of chemotherapy began in the 1940s with the first uses of nitrogen mustards and antifolate drugs. Cancer drug development since then has transformed from a low-budget, government-supported research effort to a high-stakes, multi-billion dollar industry. The targeted-therapy revolution has arrived, but the principles and limitations of chemotherapy discovered by the early researchers still apply. This article chronicles the history of modern chemotherapy and identifies remaining… 
Cancer chemotherapy: an annotated history.
  • W. Morrison
  • Biology, Medicine
    Journal of veterinary internal medicine
  • 2010
Human and veterinary cancer chemotherapy have coevolved in the context of fascinating historical, political, and scientific events created by equally fascinating individuals.
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Today, cancer research is always aimed at the study and development of new therapeutic approaches for cancer treatment, and several researchers are focused on the development of cell therapies, anti-tumor vaccines, and new biotechnological drugs that have already shown promising results in preclinical studies, therefore, in the near future, it will certainly assist to a new revolution in the field of medical oncology.
Standing in the Shifting Sands of Molecular Targeting and Precision Medicine Is the Oasis of 21st‐Century Oncology Therapeutics
Oncology-themed supplement provides a collection of expert scientific updates in clinical oncology therapeutics and highlights key areas in which the discipline of clinical pharmacology has played a prominent role.
Systemic cancer therapy: Evolution over the last 60 years
The 1940s marked the beginning of an era of important discoveries that contributed to modern concepts underlying the current practice of cancer chemotherapy, such as the log kill hypothesis reported
Genomics and the second golden era of cancer drug development.
The first golden era of cancer drug development was initiated in the 1940s and gave rise to the cytotoxic agents that dominate current cancer medicine. The second golden era is now underway in which
Chemotherapy over the Years
The article highlights the major milestones in chemotherapy through the years, including the first fruitful application of a multifaceted tactic to treat cancer in children in the 1960s and the early 1970s.
Understanding resistance to combination chemotherapy.
Search for new and novel chemotherapeutics for the treatment of human malignancies.
In this review, glimpses on types of current chemotherapeutic agents based on their action of inhibition and the new molecules that are being developed based on the scaffolds across the world as well as in this laboratory have been articulated.
Drug Development Against Metastatic Cancers
The evolution of past and current anti-cancer drug development, the limits of current strategies, and possible alternative approaches for future drug development against metastatic cancers are discussed.


Origins of cancer therapy.
  • R. Papac
  • Medicine
    The Yale journal of biology and medicine
  • 2001
The modern era of chemotherapy developed at Yale University Medical School during World War II, a fact that has been generally unrecognized until recently.
The national program for cancer chemotherapy.
Establishment and calibration of the appropriate models took ten years, and based on these correlations, in 1965 NCI instituted its present operation of drug development, and since 1965, NCI has refined this empiric blueprint as dictated by experience and new data.
The National Cancer Chemotherapy Program.
  • E. Frei
  • Medicine, Biology
  • 1982
The National Cancer Chemotherapy Program was initiated in 1955 and has increasingly emphasized and been influenced by advances in tumor biology, drug development, clinical pharmacology, and the science of clinical trials.
The Story of Taxol: Nature and Politics in the Pursuit of an Anti-Cancer Drug
Acknowledgements Abbreviations Introduction Part I. Agents: 1. Cancer chemotherapy: plant knowledge and practice Part II. Practices: 2. Act I: 1962-75 3. Act II: 1976-83 4. Act III: 1984-9 Part III.
The pharmacology and clinical use of methotrexate.
METHOTREXATE, the most widely used antimetabolite in cancer chemotherapy, has an essential role in the treatment of such diverse diseases as acute lymphocytic leukemia, non-Hodgkin's lymphoma, oste...
Intrinsic and acquired resistance to methotrexate in acute leukemia.
Methotrexate, a folic acid antagonist, is used extensively not only for the treatment of cancer but also for the treatment of rheumatoid arthritis, psoriasis, and autoimmune disease and for the
Intensive combination chemotherapy and X-irradiation in Hodgkin's disease.
It appears that the incidence of complete remissions can be increased over that obtained with a single agent and the duration of complete unmaintained remission in those patients with advanced disease is provocative even though the group is small.
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
An appreciation that both bench and clinical investigations are difficult endeavors should aid in improving clinical trial designs and give the best chance for new agents to be added to the therapeutic armamentarium.
Anticancer drug development at the US National Cancer Institute
  • C. Takimoto
  • Biology
    Cancer Chemotherapy and Pharmacology
  • 2003
This review summarizes the history of drug screening and development efforts at the NCI over the past five decades from its inception up to its current state emphasizing molecularly targeted therapies.
The National Cancer Institute: cancer drug discovery and development program.
An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future.